相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 靶点:
生物素标记CXCL2
- 级别:
科研
- 目录编号:
500-P130BT
- 抗体英文名:
Biotinylated Anti-Murine MIP-2 (CXCL2)
- 抗体名:
生物素标记CXCL2
- 标记物:
生物素标记CXCL2
- 适应物种:
小鼠
- 应用范围:
WB ELISA
- 浓度:
Biotinylated Anti-Murine MIP-2 (CXCL2)
- 库存:
500-P130BT
- 宿主:
兔
- 保质期:
12个月
- 抗原来源:
Recombinant Murine MIP-2 (CXCL2) (PeproTech catalog# 250-15)
- 是否单克隆:
多克隆
- 规格:
25ug
产品编号: 500-P130BT
资料来源:多克隆兔
制备:由高纯度(>98%)重组mMIP-2预先免疫的兔子血清制成。通过亲和层析纯化抗小鼠MIP-2特异性抗体,然后进行生物素化。
免疫原:大肠杆菌衍生的重组小鼠MIP-2(CXCL2)(PeproTech目录#250-15)
夹心ELISA:要通过夹心ELISA(使用100μl/孔抗体溶液)检测mMIP-2,需要浓度为0.25–1.0μg/ml的这种抗体。该生物素化多克隆抗体与PeproTech的多克隆抗鼠MIP-2(500-P130)结合作为捕获抗体,允许检测至少0.2–0.4 ng/孔的重组mMIP-2。
生物素化抗小鼠MIP-2(CXCL2)夹心ELISA
Western Blot:为了通过Western Blot分析检测mMIP-2,该抗体可在0.1-0.2µg/ml的浓度下使用。与兼容的二级试剂结合使用,重组mMIP-2的检测限为1.5-3.0 ng/lane,在还原或非还原条件下。
| 500-P130-50 | Rabbit Anti-Murine MIP-2 (CXCL2) | 50ug |
| 500-P130-100 | Rabbit Anti-Murine MIP-2 (CXCL2) | 100ug |
| 500-P130-1000 | Rabbit Anti-Murine MIP-2 (CXCL2) | 1000ug |
| 500-P130Bt-25 | Biotinylated Rabbit Anti-Murine MIP-2 (CXCL2) | 25ug |
| 500-P130Bt-50 | Biotinylated Rabbit Anti-Murine MIP-2 (CXCL2) | 50ug |
| 500-P130Bt-1000 | Biotinylated Rabbit Anti-Murine MIP-2 (CXCL2) | 1000ug |
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验Biotinylated Primer for Detecting Telomerase Activity Without Amplification
to be an attractive new target for designing anti-cancer agents, as well as an important diagnostic marker of human cancer (5 -7 ). For these reasons, it is necessary to develop telomerase assay methods that can be used for the quantitative measurement of telomerase
Anti-GFP/BrdU In Situ Immunostaining
IgG (Jackson ImmunoResearch, 111-096-006) Biotinylated anti-BrdU (AbCam, ab2284-125) Streptavidin-Alexa Flour 555 (Invitrogen/Molecular Probes, S21381) Goat serum Horse serum BSA 2N HCl DAPI Fluorescent mounting medium (Vectashield
on the beads was detected using biotinylated antigen/streptavidin-phycoerythrin. The method was demonstrated by isotyping antibodies directed against an anti-CD11a antibody therapeutic (RAPTIVA� /efalizumab) from the serum of a cynomolgus monkey hyper-immunized










